Status:
UNKNOWN
CogMe for the Prevention and Early Detection of Delirium
Lead Sponsor:
Rambam Health Care Campus
Collaborating Sponsors:
CogMe Ltd
Conditions:
Delirium
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
This study is designed as a prospective interventional study to evaluate the CogMe system for early detection and prevention of delirium. The study will collect physiological and cognitive measurement...
Detailed Description
Delirium is a syndrome defined as an acute disturbance of both consciousness and cognition that tends to fluctuate over time and is caused by the physiological consequences of a medical condition. It ...
Eligibility Criteria
Inclusion
- Male and female patients aged 65 years of age and older.
- Patients with an expected length of hospitalization of 4 days or longer.
- Patients who are conscious and cognitively able to provide written informed consent as suggested by a score of 0 on 4AT screening.
- Patients who have no diagnosis of delirium prior to enrollment.
Exclusion
- Male and female patients younger than 65 years of age.
- Patients with an expected length of hospitalization of less than 4 days.
- Patients with uncorrected visual or hearing impairment.
- Patients with impaired consciousness or cognitive impairment as determined by a score of 1 or more on 4AT screening.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05311761
Start Date
March 1 2022
End Date
December 31 2024
Last Update
September 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rambam Health Care Campus
Haifa, North, Israel, 3109601